CEO Presentations and Interviews

Firebrick Investor Update

Firebrick Pharma (ASX:FRE) is pleased to release an Investor Update which summarises Nasodine’s global expansion plans as a nasal antiseptic.

Originally developed as a treatment for the common cold, Nasodine will now be marketed as a nasal antiseptic in all countries (where permitted by local regulatory authorities). As a nasal antiseptic, Nasodine addresses multiple unmet medical needs and is expected to offer a valuable set of claims that should be attractive to commercial partners in all markets.

The global commercialisation strategy for Nasodine is outlined in the Investor Update along with the goals and potential news flow for calendar 2025. Read the update here.